NCT05097599: Strata PATH (Precision Indications for Approved Therapies)

NCT05097599
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Misc Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated or unstable brain metastases
https://ClinicalTrials.gov/show/NCT05097599

Comments are closed.

Up ↑